Altimmune (ALT) Change in Accured Expenses (2010 - 2026)

Altimmune (ALT) has 17 years of Change in Accured Expenses data on file, last reported at -$2.5 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$2.5 million, down 46.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 68.96% YoY), and the FY2025 annual result was $2.4 million, up 2233.04% from the prior year.
• Change in Accured Expenses slipped to -$2.5 million in Q1 2026 per ALT's latest filing, from $4.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.4 million in Q3 2022 and troughed at -$4.7 million in Q3 2024.
• A 5-year average of $193764.7 and a median of -$365000.0 in 2025 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 338.47% in 2024 and fell as far as 392.0% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$2.2 million in 2022, then jumped by 165.82% to $1.4 million in 2023, then soared by 66.55% to $2.4 million in 2024, then soared by 83.59% to $4.4 million in 2025, then sank by 157.3% to -$2.5 million in 2026.
• Business Quant data shows ALT's Change in Accured Expenses at -$2.5 million in Q1 2026, $4.4 million in Q4 2025, and $102000.0 in Q3 2025.